Page 43 - Read Online

Page 14 of 22 Guerriero et al. Hepatoma Res 2019;5:6 I http://dx.doi.org/10.20517/2394-5079.2018.108

Table 5. Circulating long noncoding RNAs as biomarkers of hepatocellular carcinoma
lncRNA Expression Body fluid Experimental setting Clinical setting Cohorts comparison Ref.
AF085935 Up Serum Single Diagnosis (early) HCC vs. HL [95]
AF085935 Up Serum Single Diagnosis (early) HCC vs. HBV carriers [95]
CTBP + LAMP2 + miR-16-2 Serum Multiple + miRNA Diagnosis HCC vs. HL + CHC [153]
+ miR-21-5p
CTBP + LAMP2 + miR-16-2 Serum Multiple + miRNA Prognosis (PFS) HCC [153]
+ miR-21-5p
DANCR Up Plasma Single Diagnosis HCC vs. HL + CHB + LC [105]
DANCR Up Plasma Single Prognosis HCC [105]
ENSG00000258332.1 + Up Serum Multiple + AFP Diagnosis HCC vs. HL + LC + CHB [96]
LINC00635
ENSG00000258332.1 + Up Serum Single Prognosis (OS) HCC [96]
LINC00635
HULC Up Plasma Single Diagnosis HCC vs. HL [104]
HULC Up Plasma Single Diagnosis HCC vs. HL [154]
HULC + LINC00152 Up Plasma Multiple + AFP Diagnosis HCC vs. HL [104]
JPX Down Plasma Single + AFP Diagnosis HCC vs. HL [101]
JPX Down Plasma Single Diagnosis HCC vs. HL [101]
JPX Down Plasma Single Prognosis HCC [101]
JUN + UCA1 Up Serum Multiple Diagnosis (early) HCC vs. HL + CHC [155]
JUN + UCA1 Up Serum Multiple + AFP Diagnosis (early) HCC vs. HL + CHC [155]
LRB1 Up Serum Single + AFP/DCP Diagnosis HCC vs. HL [102]
LRB1 Up Serum Single Prognosis (OS) HCC [102]
LINC00152 Up Plasma Single Diagnosis HCC vs. HL [104]
LINC00974 Up Plasma Single Diagnosis (early) HCC vs. HL [156]
LINC01225 Up Serum Single Diagnosis HCC vs. HL [157]
lnc-PCDH9-13:1 Up Saliva Single Diagnosis (early) HCC vs. HL + HBV carrier [107]
+ CHB + LC
LOC149086 + RP11- Up Plasma Multiple Diagnosis HCC vs. cancer free (T) [158]
160H22.5 + XLOC_014172
LOC149086 + RP11- Up Plasma Multiple Diagnosis HCC vs. cancer free (V) [158]
160H22.5 + XLOC_014172
PIVKAII + MALAT1 Up Plasma Multiple + AFP Diagnosis HCC vs. HL [159]
PVT1 + uc002mbe.2 Up Serum Multiple Diagnosis HCC vs. HL [100]
SNHG1 Up Plasma Single Diagnosis HCC vs. HL + CHB + LC [97]
SNHG1 Up Plasma Single + AFP Diagnosis HCC vs. HL + CHB + LC [97]
SPRY4-IT1 Up Plasma Single + AFP Diagnosis HCC vs. HL [160]
SPRY4-IT1 Up Plasma Single Diagnosis HCC vs. HL [160]
uc001ncr + AX800134 Serum Multiple Diagnosis (early) HCC vs. HL + HBV carriers [161]
uc003wbd Up Serum Single Diagnosis (early) HCC vs. HL [95]
uc003wbd Up Serum Single Diagnosis (early) HCC vs. HBV carriers [95]
UCA1 Up Serum Single Diagnosis HCC vs. HL + CHC [99]
UCA1 Up Serum Single Prognosis (PSF) HCC [103]
UCA1 + WRAP53 Up Serum Multiple + AFP Diagnosis HCC vs. HL + CHC [99]
UCA1 + WRAP53 Up Serum Multiple Diagnosis HCC vs. HL + CHC [99]
WRAP53 Up Serum Single Diagnosis HCC vs. HL + CHC [99]
WRAP53 Up Serum Single Prognosis (PSF) HCC [99]
XIST Down Plasma Single Prognosis HCC [101]
ZFAS1 Up Plasma Single + AFP Diagnosis HCC vs. HL (T) [98]
ZFAS1 Up Plasma Single + AFP Diagnosis HCC vs. HL + CHB + LC (V) [98]
ZFAS1 Up Plasma Single Diagnosis HCC vs. HL (T) [98]
ZFAS1 Up Plasma Single Diagnosis HCC vs. HL + CHB + LC (V) [98]
lncRNA: long noncoding RNA; AFP: alpha fetoprotein; DCP: des-carboxyprothrombin; CHC: chronic hepatitis C; CHB: chronic hepatitis B;
HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HL: healthy liver; LC: liver cirrhosis; (T): training set; (V): validation set; OS: overall
survival; PFS: progression free survival

5p was decreased in non-responder patients compared to responders, suggesting this miRNA as a candidate
serum biomarker for predicting response to sorafenib.